Rallybio FY 2023: net loss $74.6M; diluted EPS −$1.84

Key figures from this report

These are the numbers Rallybio reported for the year ended Dec 31, 2023, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

1. Net income−$74.6MAgainst −$66.7M in FY 202210-K income statement, on EDGAR
2. Diluted EPS−$1.84Against −$2.09 in FY 202210-K income statement, on EDGAR
3. Cash and cash equivalents$24.5M−57% from $57.0M in FY 2022Cash and equivalents only; the company page adds short-term investments.10-K balance sheet, on EDGAR
4. Cash from operations−$60.3MAgainst −$57.3M in FY 202210-K cash flow statement, on EDGAR

Every year in the financial tables